Merz Neurosciences announced the launch of Xeomin (incobotulinumtoxinA) in a new 200 Unit single-dose vial. 

The new 200 Unit size supports dosing options for Xeomin’s recently approved indication for adult upper limb spasticity. It is a neuromuscular blocker that blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings

RELATED: Botox Gains Lower Limb Spasticity Indication

Xeomin is already approved for use in cervical dystonia in adults, to reduce severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients; and for blepharospasm in adults previously treated with onabotulinumtoxinA.

It is currently available as 50 and 100 Unit strengths in single-use vials.

For more information call (888) 4-XEOMIN or visit